- Home
- NTIP vs KALA Comparison
NTIP vs KALA Comparison
Compare NTIP & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- KALA
- Stock Information
- Founded
- NTIP 1990
- KALA 2009
- Country
- NTIP United States
- KALA United States
- Employees
- NTIP N/A
- KALA N/A
- Industry
- NTIP Multi-Sector Companies
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- NTIP Miscellaneous
- KALA Health Care
- Exchange
- NTIP Nasdaq
- KALA Nasdaq
- Market Cap
- NTIP 32.0M
- KALA 26.2M
- IPO Year
- NTIP 1998
- KALA 2017
- Fundamental
- Price
- NTIP $1.42
- KALA $7.14
- Analyst Decision
- NTIP
- KALA Strong Buy
- Analyst Count
- NTIP 0
- KALA 3
- Target Price
- NTIP N/A
- KALA $14.00
- AVG Volume (30 Days)
- NTIP 35.4K
- KALA 198.2K
- Earning Date
- NTIP 08-11-2025
- KALA 08-05-2025
- Dividend Yield
- NTIP 7.07%
- KALA N/A
- EPS Growth
- NTIP N/A
- KALA N/A
- EPS
- NTIP N/A
- KALA N/A
- Revenue
- NTIP $250,000.00
- KALA N/A
- Revenue This Year
- NTIP N/A
- KALA N/A
- Revenue Next Year
- NTIP N/A
- KALA N/A
- P/E Ratio
- NTIP N/A
- KALA N/A
- Revenue Growth
- NTIP N/A
- KALA N/A
- 52 Week Low
- NTIP $1.16
- KALA $2.92
- 52 Week High
- NTIP $1.78
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- NTIP 63.69
- KALA 59.52
- Support Level
- NTIP $1.40
- KALA $5.35
- Resistance Level
- NTIP $1.46
- KALA $8.49
- Average True Range (ATR)
- NTIP 0.05
- KALA 0.81
- MACD
- NTIP 0.00
- KALA 0.17
- Stochastic Oscillator
- NTIP 78.95
- KALA 57.01
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.